Compare MLEC & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLEC | ACXP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 6.8M |
| IPO Year | N/A | 2021 |
| Metric | MLEC | ACXP |
|---|---|---|
| Price | $0.42 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | ★ 131.7K | 79.9K |
| Earning Date | 01-30-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.42 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 170.36 | N/A |
| 52 Week Low | $0.39 | $3.17 |
| 52 Week High | $8.00 | $25.00 |
| Indicator | MLEC | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 36.36 | 46.95 |
| Support Level | $0.41 | $3.98 |
| Resistance Level | $0.48 | $4.36 |
| Average True Range (ATR) | 0.05 | 0.39 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 24.66 | 62.89 |
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.